Advertisement
Evotec, Novo Nordisk Roll Out LAB EN To Accelerate Translation In Cardiometabolic Diseases
(RTTNews) - Evotec SE (EVO, EVOTF.PK) and Novo Nordisk A/S (NVO) announced Tuesday a translational drug discovery accelerator called LAB eN, which aims to nurture early research from academic institutions into novel therapeutics.
LAB eN is a unique engagement model that combines Evotec's multimodality drug discovery and pre-clinical development capabilities with Novo Nordisk's therapeutic, clinical, and commercial expertise.
LAB eN will focus on addressing unmet need in cardiometabolic diseases as well as rare blood and rare endocrine disorders.
LAB eN has already signed on four academic institutions to participate: Harvard University, Mass General Brigham, Yale University, and Beth Israel Deaconess Medical Center.
read more
Novo Nordisk Stock Climbs On Higher Q1 Results; Cuts FY25 Outlook
Shares of Novo Nordisk A/S were gaining around 6 percent in Denmark as well as around 7 percent in the pre-market activity on the NYSE, after the Danish drug major reported Wednesday higher profit and sales in its first quarter, mainly reflecting improved results of its blockbuster weight loss drug Wegovy. Meanwhile, the company trimmed fiscal 2025 outlook for sales and operating profit growth...
RTTNews
|
7 일 전
Novo Nordisk Plans $4.1 Bln NC Facility To Boost Obesity Drug Supply
Danish drug maker Novo Nordisk announced its plans to invest $4.1 billion or about 27 billion Danish kroner to build a new manufacturing plant in Clayton, North Carolina with a view to expanding its manufacturing capacity in the United States. In the new plant, the company plans to produce current and future injectable treatments for people with obesity and other serious chronic diseases.
RTTNews
|
323 일 전
Novo Nordisk Says FLOW Trial Achieves Primary Endpoint
Novo Nordisk A/S (NVO) announced Tuesday the headline results from the kidney outcomes trial FLOW. The announcement follows the decision to stop the trial early due to efficacy.
RTTNews
|
435 일 전
Novo Nordisk Slashes US List Prices Of Several Insulin Products By Up To 75%
Healthcare company Novo Nordisk Inc. (NVO) announced Tuesday it is lowering the U.S. list prices of several pre-filled insulin pens and vials by up to 75% for people living with type 1 and type 2 diabetes.
RTTNews
|
792 일 전
Swiss Franc Weakens Against Majors
The Swiss franc fell against its major counterparts in the New York session on Wednesday.
The franc edged down to 1.1182 against the pound and 0.8436 against the greenback, from an early high of 1.1117 and a 5-day high of 0.8324, respectively.
RTTNews
|
21 분 전
Pound Falls Against U.S. Dollar, Euro
The pound dropped against the U.S. dollar and the euro in the New York session on Wednesday.
RTTNews
|
1 시간 31 분 전
E.ON Confirms Outlook After Higher Q1 Adj. Earnings
German utility E.ON SE reported Wednesday a significant increase in its first-quarter adjusted earnings and Group EBITDA with growth in all three core segments. Further, the firm affirmed its guidance for 2025 and its outlook through 2028. On the XETRA in Germany, E.ON shares were gaining around 1.36 percent.
RTTNews
|
6 시간 47 분 전
Yen Rises Against Majors
The Japanese yen strengthened against other major currencies in the European session on Wednesday.
RTTNews
|
9 시간 11 분 전
